In this three-center open-label study from November 2011 to May 2013 , we randomly assigned 189 patients with advanced Child-Pugh class B or C HCC patients into two groups , one group with 95 patient to receive sorafenib ( 400 mg a time , twice a day ) and the other group with 94 patients to receive best supportive care .